Full Text View
Tabular View
Study Results
Related Studies
Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer
This study has been completed.
Study NCT00537095   Information provided by AstraZeneca

First Received on September 27, 2007.   Last Updated on January 9, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Thyroid Neoplasms
Additional conditions recognized in this trial
Adenocarcinoma, Follicular
Neoplasms
Thyroid Diseases
More general conditions related to this trial
Adenocarcinoma
Carcinoma
Endocrine Gland Neoplasms
Endocrine System Diseases
Head and Neck Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
Vandetanib
Placebo
Sponsors listed in this trial
AstraZeneca


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services